2023-507885-21-00招募中2 期
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Longterm Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Argenx
- 入组人数
- 88
- 试验地点
- 41
- 主要终点
- Incidence of TEAEs and SAEs by system organ class (SOC) and preferred term (PT). TEAEs and SAEs are monitored throughout the entire study duration.
研究概览
简要总结
To assess the long-term safety and tolerability of efgartigimod PH20 SC (efgartigimod co-formulated with recombinant human hyaluronidase PH20 [rHuPH20] for subcutaneous [SC] administration)
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Optional Dosing Frequency Substudy
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Ability to understand the requirements of the trial, provide written informed consent (including consent for the use and disclosure of research-related health information), willingness and ability to comply with the trial protocol procedures (including required trial visits) of this trial.
- •Male or female patient with 1 of the following options: - Have completed the Week-48 visit of Stage B of the ARGX-113-1802 trial and are considered to be eligible for treatment with efgartigimod PH20 SC; or - Have deteriorated during Stage B of the ARGX-113-1802 trial and are considered to be eligible for treatment with efgartigimod PH20 SC, or - Have been offered the participation in the OLE trial due to early termination of the ARGX-113-1802 trial (because sufficient events for the primary endpoint analysis of the that trial have been reached and it is stopped) and are considered to be eligible for treatment with efgartigimod PH20 SC treatment; or - Have completed the Week-48 visit of the previous cycle of the OLE trial and are considered to be eligible to continue with efgartigimod PH20 SC treatment.
- •Women of childbearing potential who have a negative urine pregnancy test at baseline before IMP administration.
- •Women of childbearing potential must use an acceptable method of contraception from signing the ICF until the date of the last dose of IMP
排除标准
- •Week-48/ED visit in the ARGX-113-1802 trial or the Week-48 visit of the previous OLE participation occurred more than 14 days prior to SD1 of the OLE trial or the start of a new treatment cycle in the OLE trial and more than 21 days since the last dose of IMP.
- •Pregnant and lactating women and those intending to become pregnant during the trial.
- •Patients with clinical evidence of other significant serious disease or patients who underwent a recent or have a planned major surgery, or patients who (intend to) use prohibited medications and therapies during the trial, or any other reason which could confound the results of the trial or put the patient at undue risk.
结局指标
主要结局
Incidence of TEAEs and SAEs by system organ class (SOC) and preferred term (PT). TEAEs and SAEs are monitored throughout the entire study duration.
Incidence of TEAEs and SAEs by system organ class (SOC) and preferred term (PT). TEAEs and SAEs are monitored throughout the entire study duration.
Incidence of clinically significant laboratory abnormalities. Blood sampling for laboratory analysis is taken at every study visit.
Incidence of clinically significant laboratory abnormalities. Blood sampling for laboratory analysis is taken at every study visit.
次要结局
- Efficacy; Change from baseline over time in the following scores and measurements: − Adjusted INCAT score; − MRC Sum score; − 24-item I-RODS disability scores; − Mean grip strength assessed by Martin vigorimeter; − TUG score. Percentage of patients without clinical deterioration over time, defined by adjusted INCAT increase ≥1 point compared to baseline.
- Immunogenicity; - Percentage of patients with and titers of binding antibodies (BAb) towards efgartigimod; and the presence of neutralizing antibodies (NAb) against efgartigimod.
- Pharmacokinetics; - Efgartigimod serum concentrations (during the first 48-week treatment cycle [followed by a safety follow-up period, if applicable]).
- Pharmacodynamics; - Changes from baseline over time of serum IgG levels (total). Efficacy, immunogenicity, pharmacokinetic and pharmacodynamic endpoints are assessed at every study visit
- Additional Patient-reported Outcome; Change from baseline over time in: − Health-related quality-of-life questionnaire (EQ-5D-5L); − Brief Pain Inventory – Short Form (BPI-SF); − 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9); − Rasch-transformed-Fatigue Severity Scale (RT-FSS); − Hospital Anxiety and Depression Scale (HADS). Patient report outcomes are assessed at every study visit with the exception of visit 2 (week 4)
- Percentage of patients performing self-administration over time.
- Percentage of patients with treatment administered by caregiver over time.
- This is mock end point to allow the upload of the full translation of endpoint number 5.
- This is mock end point to allow the upload of the full translation of endpoint number 1.
研究者
Chief Scientific Officer Vice President Clinical Development
Scientific
Argenx
研究点 (41)
Loading locations...
相似试验
已完成
3 期
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous PemphigoidBullous Pemphigoid2024-515832-59-00Argenx43
进行中（未招募）
3 期
一项在活动性特发性炎性肌病成人受试者中探究 efgartigimod PH20 SC 有效性和安全性的研究CTR2025471130
招募中
3 期
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Subcutaneously in Children With Generalized Myasthenia GravisGeneralized Myasthenia Gravis2023-507379-23-00Argenx17
Enrolling By Invitation
3 期
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory MyopathyActive Idiopathic Inflammatory MyopathyPolymyositisImmune-Mediated Necrotizing MyopathyDermatomyositisMyositisAntisynthetase SyndromeNCT05979441argenx240
招募中
2 期
An Open-Label Extension Study for Participants with PAH Who Have Previously Participated in a Clinical Trial with PF-07868489Pulmonary Arterial Hypertension2025-521155-23-00Pfizer Inc.5